Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover we detect TERT promotor mutation status in the recurrent tumors (n = 21) of these UBC patients.
|
31521529 |
2020 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aRNA driven by a tumor-specific mutant human telomerase reverse transcriptase (hTERT) promoter is created to interact with iRNA to expose UAS again in bladder cancer.
|
29084575 |
2017 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
|
28049011 |
2017 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
In our study, we aimed to construct a synthetic combination module driven by a super artificial hTERT promoter and to investigate its influence on the malignant phenotypes of bladder cancer.
|
26743236 |
2016 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Similar to urothelial carcinoma, we found a relatively higher rate of TERT-mut among nonenteric-type adenocarcinomas further supporting the potential utility of TERT-mut urine-based screening assay for bladder cancer.
|
26980028 |
2016 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysing only previously reported point mutations, TERT mutations were found in 55% of patients with bladder cancer (independent of stage), FGFR3 mutations in 30% of patients with bladder cancer, PIK3CA in 14% and TP53 mutations in 12% of patients with bladder cancer.
|
26901314 |
2016 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two recurrent point mutations in the promoter region of telomerase reverse transcriptase (TERT)--the key subunit of telomerase--have recently been identified in melanoma as well as a small sample of bladder cancer cell lines.
|
27040924 |
2016 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The detection of TERT-mut in urine is under investigation as a potential urine-based molecular-screening assay for bladder cancer.
|
26965579 |
2016 |
Bladder Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TERT expression levels are consistent with clinical severity and prognosis of bladder cancer.
|
26143634 |
2015 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
|
25657201 |
2015 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, recurrent mutations within the core promoter of the human telomerase reverse transcriptase (TERT) gene generating consensus binding sites for ETS transcription factor family members were described in melanomas and other malignancies (e.g. bladder cancer, hepatocellular carcinoma).
|
25997473 |
2015 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic analysis of bladder cancer has revealed a number of frequently altered genes, including frequent alterations of the telomerase (TERT) gene promoter, although few altered genes have been functionally evaluated.
|
25225064 |
2014 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
|
24018021 |
2014 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, mutations in telomerase (TERT) gene promoter were found in sporadic and familial melanoma and subsequently in several cancer models, notably in gliomas, thyroid cancer and bladder cancer.
|
25048572 |
2014 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Further clinical confounding factor, namely, tumor grade/stage level of cases, supports the genotypic data with TERT and SLC14A1 showing a risk for BC susceptibility.
|
25218484 |
2014 |
Bladder Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also evaluated the sequence of the TERT promoter in a separate series of 14 early bladder neoplasms and matched follow-up urine samples to determine whether urine TERT status was an indicator of disease recurrence.
|
24121487 |
2013 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
CTD_human |
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.
|
19151717 |
2009 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
LHGDN |
Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.
|
18425331 |
2008 |
Bladder Neoplasm
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Analysis of hTERT expression in exfoliated cells from patients with bladder transitional cell carcinomas using SYBR green real-time fluorescence quantitative PCR.
|
17961306 |
2007 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we evaluated combination therapy of adenoviral vector Ad-hTERT-CD encoding E. coli cytosine deaminase (CD) driven by the hTERT promoter and low-dose etoposide (0.1 microg/mL) for treating bladder cancer.
|
17047058 |
2006 |
Bladder Neoplasm
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
|
16734859 |
2006 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
LHGDN |
Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer.
|
15900578 |
2005 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
This suggests that the hTERT gene might be a suitable gene target for bladder cancer therapy.
|
16153224 |
2005 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methylation of DAPK, BCL2, and TERT in urine sediment DNA from bladder cancer patients was detected in the majority of samples (78%), whereas they were unmethylated in the urine sediment DNA from age-matched cancer-free individuals.
|
15569975 |
2004 |
Bladder Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
|
15636669 |
2004 |